冠盛股份(605088.SH)半年度淨利潤預增55.69%
格隆匯7月15日丨冠盛股份(605088.SH)公佈2022年半年度業績預增公吿,公司預計2022年半年度實現歸屬於母公司所有者的淨利潤為1億元,與上年同期相比,將增加3590.89萬元,同比增長55.69%;預計2022年半年度實現歸屬於母公司所有者的扣除非經常性損益的淨利潤為8284.56萬元,與上年同期相比,將增加4134.76萬元,同比增長99.64%。
本期業績預增的主要原因:
(一)主營業務影響:公司持續穩健推進全球佈局,產品競爭優勢與服務能力持續提升,營業收入實現預期增長。強化生產效率和成本管理,綜合成本水平下降,毛利率同比顯著提升。
(二)受益於美元對人民幣匯率波動,財務費用同比大幅下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.